Following two small Phase 1 trials, Cornerstone Pharmaceuticals announced Thursday that it has secured FDA-backing for pivotal trials of its lead drug in AML and late-stage pancreatic cancer.
Monoclonal antibodies? So passé. Cancer metabolism drugs are emerging as the therapeutic to watch, or so says Cornerstone Pharmaceuticals CEO Steve Carchedi. Cornerstone’s approach is to develop anticancer drugs that target mitochondrial metabolism – in essence cutting off the energy supply that allows cancer cells to grow and develop. Its lead candidate, CPI-613, inhibits two enzymes that are […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.